Search Results

For healthcare professionals or patients with specific medical questions for Teva, please contact us here

Teva makes its best efforts and invests many resources in order to provide all our customers with an equal, respectable, accessible and professional service.

Effective Date: March 1, 2021

Teva is leveraging advanced bioanalytics to help lower the cost of drug development.

Teva has invested over $500 million dollars to build a new state-of-the-art biological manufacturing plant in Ulm Germany.

Last year, Teva shipped over 600,000 pallets globally across 45 countries, including 150,000 pallets in the US.

The more Teva Biosimilars can do to advocate for a more cost effective approach for the process, we believe the more sustainable the future for biosimilars.

Teva Biosimilars understands the value of strategic partnerships.

Teva is determined to lead the way in innovating quality, affordable and accessible biosimilars.

At Teva, we don’t believe cost should be a barrier between people and the medicines they need.